VEGFR2-169
Also known as: KDR‑169, VEGFR2 peptide 169‑177
Source VEGFR2-169 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
VEGFR2‑169 is a 9‑mer synthetic peptide derived from the extracellular domain of vascular endothelial growth factor receptor 2, evaluated as an anti‑angiogenic cancer vaccine in early‑phase clinical trials.
Mechanism of Action
induces CD8+ T‑cell responses against VEGFR2‑expressing endothelial cells, inhibiting tumor angiogenesis
Routes of Administration
Goals & Uses
- Anti‑angiogenesisVascularModerate
- Cancer immunotherapyOncologyModerate
Contraindications
- Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
- Immunosuppressive therapyPharmacologicalModerate
Adverse Effects
- Injection‑site erythemaLocalCommon
- Fever / flu‑like symptomsSystemicUncommon
Drug Interactions
- TNF‑α inhibitorsModerate
- CorticosteroidsModerate
Population Constraints
- Pregnant womenReproductiveAbsolute
- Children < 12 yAgeRelative
Regulatory Status
- European UnionInvestigationalNo marketing authorization
- United StatesInvestigationalPhase I/II oncology trials only
- United KingdomInvestigationalClinical trial use only
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is VEGFR2-169?
VEGFR2‑169 is a 9‑mer synthetic peptide derived from the extracellular domain of vascular endothelial growth factor receptor 2, evaluated as an anti‑angiogenic cancer vaccine in early‑phase clinical trials.
What is VEGFR2-169 used for?
VEGFR2-169 is educationally associated with: Anti‑angiogenesis, Cancer immunotherapy. Educational only — not medical advice.
How is VEGFR2-169 administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of VEGFR2-169?
Reported adverse effects include: Injection‑site erythema, Fever / flu‑like symptoms. This list is not exhaustive — consult a qualified clinician.
Who should avoid VEGFR2-169?
Recorded contraindications: Autoimmune disease, Immunosuppressive therapy. Consult a qualified clinician before use.